An open, randomized, parallel group, multi-center study on the effect of a resume of Renal Anemia Treatment by Erythropoietin supplemented with Iron and vitamin C on the Prognosis in Hemodialysis Patients

An open, randomized, parallel group, multi-center study on the effect of a resume of Renal Anemia Treatment by Erythropoietin supplemented with Iron and vitamin C on the Prognosis in Hemodialysis Patients - ACTIVE

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000316

Enrollment

450

Registered

2006-04-12

Start date

2006-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal anemia in maintenance dialysis patients

Interventions

Protocolized treatment for renal anemia that was proposed by ACTIVE study group. Doses of erythropoietin, iron and vitamin C were changed every month by serum ferritin level and Hb concentration acco

Attending physician determined the doses of erythropoietin and iron.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with renal anemia receiving erythropoietin who have maintained dialysis therapy for over 1 year.

Exclusion criteria

Exclusion criteria: 1) Patients with malignancy, infection and severe liver and lung diseases, 2)Patients receiving steroids and immunosuppressants

Design outcomes

Primary

Measure	Time frame
1) required doses of erythropoietin and iron for maintaining Hb level>11 g/dl 2) nutritional state 3) cardiovascular event, 4) hospitaization, 5)survival rate	—

Countries

Japan

Contacts

Public ContactTakahiro Kuragano

ACTIVE study office Department of kidney and dialysis

kuragano@hyo-med.ac.jp0798-45-6521

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026